Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström
Company release Nanoform Finland Plc November 19, 2024 20.45 Finnish…
Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen
Company release Nanoform Finland Plc November 19, 2024 20.45 Finnish…
Nanoform Q3 2024 report: Record number of new projects signed
Nanoform Q3 2024 report: Record number of new projects signed…
Invitation to Nanoform’s Q3 2024 Report Presentation
Press release Nanoform Finland Plc November 4, 2024 11:00 a.m.…
Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release
Company release Nanoform Finland Plc October 25, 2024 16.15 Finnish…
Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019
Company release Nanoform Finland Plc October 22, 2024 19.20 Finnish…
Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants
Press release Nanoform Finland Plc September 5, 2024 08:10 a.m.…
Nanoform Q2 report: All business targets for 2024 on track
Company Announcement Nanoform Q2 report: All business targets for 2024…
Invitation to Nanoform’s Q2 2024 Report Presentation
Press release Nanoform Finland Plc August 16, 2024 11:00 a.m.…
NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT
Press release Nanoform Finland Plc August 15, 2024 08:10 a.m.…
Nanoform Finland Plc – Manager’s Transactions – Miguel Calado
Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish…
Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström
Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish…
Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen
Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish…
Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma
Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish…
Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2024 on remuneration of the Board of Directors
Company release Nanoform Finland Plc June 14, 2024 17:00 Finnish…
Nanoform’s biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned
Company Announcement Nanoform Finland Plc May 30, 2024 08:10 a.m.…
Disclosure of Major Holdings under Law 163/2024
Company Release Nanoform Finland Plc May 29, 2024 12.30 Finnish…
Disclosure of Major Holdings under Law 163/2024
Company Release Nanoform Finland Plc May 29, 2024 12.30 Finnish…
Invitation to Nanoform’s Q1 2024 Report Presentation
Press release Nanoform Finland Plc May 16, 2024 11:00 a.m.…
Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit
Press Release Nanoform Finland Plc May 7, 2024 09.10 EEST…
Disclosure of Major Holdings under Law 163/2024
Company Release Nanoform Finland Plc April 26, 2024 11.00 Finnish…
New shares of Nanoform registered with the trade register
Company Release Nanoform Finland Plc April 25, 2024 17.00 Finnish…
Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines
Inside information Nanoform Finland Plc April 24, 2024 22.50 Finnish…
Nanoform announces its intention to carry out a new share issue of approximately 7 million new shares to invest in commercialization of nanoparticle enabled formulations for next generation medicines
Inside information Nanoform Finland Plc April 24, 2024 18.31 Finnish…
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Company release Nanoform Finland Plc April 16, 2024 13.50 Finnish…
Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 16, 2024
Company release Nanoform Finland Plc April 16, 2024 13.40 Finnish…
Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan
Press Release Nanoform Finland Plc April 11, 2024 09.00 EEST…
Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer
Press release Nanoform Finland Plc April 9, 2024 09.00 EEST…
Nanoform Finland Plc: Certified Adviser change to Carnegie Investment Bank Ab
Company release Nanoform Finland Plc April 8, 2024 09.00 Finnish…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals
Company release Nanoform Finland Plc March 26, 2024 19.30 Finnish…
Notice to the Annual General Meeting of NANOFORM FINLAND Plc
Notice to the Annual General Meeting of NANOFORM FINLAND Plc…
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen Nanoform Finland Oyj:n (”Yhtiö”)…
Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 and 1/2020
Company release Nanoform Finland Plc March 12, 2024 18.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc March 6, 2024 08.30 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc March 6, 2024 08.30 Finnish…
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Company release Nanoform Finland Plc March 6, 2024 08.30 Finnish…
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Company release Nanoform Finland Plc March 6, 2024 08.30 Finnish…
Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations
Press Release Nanoform Finland Plc February 29, 2024 08:11 a.m.…
Strong momentum in Project Nanoenzalutamide
Company Announcement Nanoform Finland Plc February 29, 2024 08:10 a.m.…
Invitation to Nanoform’s Q4 and FY 2023 Report Presentation
Press release Nanoform Finland Plc February 16, 2024 11:00 a.m.…
Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research Into Nanoparticle Enabled Formulations for Next Generation Medicines
Inside information Nanoform Finland Plc February 15, 2024 12:45 Finnish…
Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
Inside information Nanoform Finland Plc January 26th, 2024 11:20 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – David Rowe
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Edward Hæggström
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Peter Hänninen
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Christian Jones
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Johanna Kause
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Antonio Da Silva
Company release Nanoform Finland Plc January 10, 2024 23.00 Finnish…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees
Company release Nanoform Finland Plc January 10, 2024 23:00 Finnish…
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Press release Nanoform Finland Plc January 5, 2023 08:10 Finnish…
Correction: Share subscriptions based on Nanoform Finland Plc’s stock options 1/2020 and 2/2019
Company release Nanoform Finland Plc December 18, 2023 16.00 Finnish…
Share subscriptions based on Nanoform Finland Plc’s stock options 1/2019 and 2/2019
Company release Nanoform Finland Plc December 5, 2023 18.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Company release Nanoform Finland Plc November 29, 2023 09.00 Finnish…
Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation
Company Announcement Nanoform Finland Plc November 22, 2023 08:10 a.m.…
Invitation to Nanoform’s Q3 2023 Interim Report
Press release Nanoform Finland Plc November 8, 2023 11:00 a.m.…
Nanoform grant Global STARMAP[®] AI License to AstraZeneca
Press release Nanoform Finland Plc October 23, 2023 08:10 Finnish…
Nanoformed TargTex oncology drug candidate TTX101 receives FDA Orphan Drug Designation
Press release Nanoform Finland Plc October 19, 2023 12:15 Finnish…
Nanoform Finland Plc – Managers’ transactions – Albert Hæggström
Company release Nanoform Finland Plc September 13, 2023 17:30 Finnish…
Nanoform Finland Plc – Managers’ transactions – Antonio Da Silva
Company release Nanoform Finland Plc September 13, 2023 17:30 Finnish…
Nanoform Finland Plc – Managers’ transactions – Christian Jones
Company release Nanoform Finland Plc September 13, 2023 17:30 Finnish…
Nanoform Finland Plc – Managers’ transactions – Peter Hänninen
Company release Nanoform Finland Plc September 13, 2023 17:30 Finnish…
Nanoform Finland Plc – Managers’ transactions – David Rowe
Company release Nanoform Finland Plc September 13, 2023 17:30 Finnish…
Nanoform Finland Plc – Managers’ transactions – Johanna Kause
Company release Nanoform Finland Plc September 13, 2023 17:30 Finnish…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company release Nanoform Finland Plc September 12, 2023 4:30 p.m.…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc August 29, 2023 18:10 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc August 29, 2023 18:10 Finnish…
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Company release Nanoform Finland Plc August 29, 2023 18:10 Finnish…
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Company release Nanoform Finland Plc August 29, 2023 18:10 Finnish…
Nanoform Q2 2023 – A record 11 new customer projects signed and targeting first license/commercial supply agreement in 2024
Company Announcement Nanoform Finland Plc August 24, 2023 08:10 a.m.…
Invitation to Nanoform’s Q2 2023 Interim Report
Press release Nanoform Finland Plc August 10, 2023 11:00 a.m.…
Nanoform and Celanese Demonstrate Enhanced Drug Delivery through the Power of Smaller Implants
Press release Nanoform Finland Plc June 15, 2023 08:10 a.m.…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc May 31, 2023 09:30 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc May 31, 2023 09:30 Finnish…
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Company release Nanoform Finland Plc May 31, 2023 09:30 Finnish…
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Company release Nanoform Finland Plc May 31, 2023 09:30 Finnish…
Nanoform Q1 2023 interim report – A strong start to the new year
Company Announcement Nanoform Finland Plc May 25, 2023 08:10 a.m.…
Invitation to Nanoform’s Q1 2023 Interim Report
Press release Nanoform Finland Plc May 11th, 2023 11:00 a.m.…
FIMEA renews Nanoform’s GMP license and Nanoform starts clinical API manufacturing of a blockbuster medicine candidate
Press release Nanoform Finland Plc May 9, 2023 15.00 Finnish…
Share subscriptions based on Nanoform Finland Plc’s stock options 3-5/2019 and 1/2020
Company release Nanoform Finland Plc April 12, 2023 15:01 Finnish…
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Company release Nanoform Finland Plc April 12, 2023 15.00 Finnish…
Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 12, 2023
Company release Nanoform Finland Plc April 12, 2023 14:00 Finnish…
Notice to the Annual General Meeting of NANOFORM FINLAND Plc
Company Announcement Nanoform Finland Plc March 15, 2023 15:00 Finnish…
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen
Yhtiötiedote Nanoform Finland Oyj 15 Maaliskuuta, 2023 15:00 Suomen aikaa…
Nanoform reports continued progress in 2022 and sets new targets for 2023
Company Announcement Nanoform Finland Plc February 28, 2023 08:10 a.m.…
Invitation to Nanoform Q4 and FY2022 report
Press release Nanoform Finland Plc February 14th, 2023 11:00 a.m.…
Share subscriptions based on Nanoform Finland Plc’s stock options 3-5/2019 and 1/2020
Company release Nanoform Finland Plc January 11, 2023 09:00 a.m.…
Nanoform Finland Plc – Manager’s transactions – Antonio da Silva
Company release Nanoform Finland Plc January 11, 2023 09:00 a.m.…
Nanoform appoints Antonio da Silva as Chief of Business Operations (CBO) and member of the Management Team
Company release Nanoform Finland Plc December 20th, 2022 15:05 Finnish…
Nanoform CTO Niklas Sandler transitions to technology advisor to the CEO
Company release Nanoform Finland Plc December 20th, 2022 15:05 Finnish…
Nanoform financial calendar for 2023
Company Announcement Nanoform Finland Plc December 7th, 2022 11.00 a.m.…
Nanoform Q3 and 9M 2022 report: Continued solid progress
Highly promising in-vivo data for the treatment of glioblastoma multiforme…
Invitation to Nanoform’s Interim Report January-September 2022
Press release Nanoform Finland Plc November 15, 2022 11:00 a.m.…
Nanoform Finland Plc – Manager’s transactions – Niklas Sandler
Company release Nanoform Finland Plc October 27, 2022 19:15 Finnish…
TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug
Press release Nanoform Finland Plc October 17, 2022 08:10 a.m.…
Nanoform unveils new patient statue
We were delighted to gather the entire Nanoform team for…
Nanoform Finland Plc – Manager’s transactions – Niklas Sandler
Company release Nanoform Finland Plc September 7, 2022 18:00 Finnish…
Share subscriptions based on Nanoform Finland Plc’s stock options 2-3/2019 and 1/2020
Company release Nanoform Finland Plc September 6, 2022 06:00 p.m.…
Nanoform Q2 and H1 2022 report: Strong momentum continues
Company Announcement Nanoform Finland Plc August 25, 2022 08:10 a.m.…
Invitation to Nanoform’s Interim Report January-June 2022
Press release Nanoform Finland Plc August 10th, 2022 11:00 a.m.…
Nanoform and Pharmanovia to breathe new life into iconic medicines
Press release Nanoform Finland Plc July 14th, 2022 08:10 a.m.…
Nanoform Chief of Business Operations Gonçalo Andrade steps down
Company release Nanoform Finland Plc June 13, 2022 18:00 Finnish…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Company release Nanoform Finland Plc June 13, 2022 10:00 a.m.…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc June 13, 2022 10:00 a.m.…
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Company release Nanoform Finland Plc June 13, 2022 10:00 a.m.…
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Company release Nanoform Finland Plc June 13, 2022 10:00 a.m.…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company release Nanoform Finland Plc June 6, 2022 07:30 p.m.…
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Company release Nanoform Finland Plc June 6, 2022 07:30 p.m.…
Share subscriptions based on Nanoform Finland Plc’s stock options 1-2/2019 and 1/2020
Company release Nanoform Finland Plc June 6, 2022 07:30 p.m.…
Nanoform Finland Plc – Manager’s transactions – Niklas Sandler
Company release Nanoform Finland Plc June 2, 2022 15:45 Finnish…
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Company release Nanoform Finland Plc May 30, 2022 12:30 p.m.…
Nanoform 1Q 2022 report: Quarterly record of new projects and new customers
Company Announcement Nanoform Finland Plc May 24, 2022 08:10 a.m.…
Invitation to Nanoform’s Interim Report January-March 2022
Press release Nanoform Finland Plc May 10th, 2022 11:00 a.m.…
Nanoform launches “STARMAP® Online” placing AI-power at the fingertips of medicine developers
Press release Nanoform Finland Plc May 4th, 2022 09:00 a.m.…
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Company release Nanoform Finland Plc April 12, 2022 07:05 p.m.…
Nanoform Finland Plc – Manager’s transactions – Niklas Sandler
Company release Nanoform Finland Plc April 12, 2022 07:05 p.m.…
Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs
Company release Nanoform Finland Plc April 12, 2022 07:00 p.m.…
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Company release Nanoform Finland Plc April 12, 2022 07:00 p.m.…
Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 12, 2022
Company release Nanoform Finland Plc April 12, 2022 12:30 p.m.…
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Company release Nanoform Finland Plc March 25, 2022 04.45 p.m.…
New shares of Nanoform registered with the trade register
New shares of Nanoform registered with the trade register March…
Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA
Inside information Nanoform Finland Plc March 22, 2022 23:45 Finnish…
Nanoform announces its intention to carry out a new share issue to raise approximately EUR 25 million to prepare for GMP manufacturing in the USA
Inside information Nanoform Finland Plc March 22, 2022 18:31 Finnish…
Notice to the Annual General Meeting of NANOFORM FINLAND Plc
The shareholders of Nanoform Finland Plc (the “Company”) (business ID:…
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen
Nanoform Finland Oyj:n (”Yhtiö”) (Y-tunnus: 2730572-8) osakkeenomistajat kutsutaan varsinaiseen yhtiökokoukseen,…
Nanoform triples its GMP capacity and adds high potent handling (OEL <30 ng/m3) capabilities to its Helsinki facility to meet increasing demand.
In today’s pharmaceutical development pipeline, about 70% to 90% of…
Nanoform 4Q and full year 2021 report: accelerating GMP growth
Company Announcement Nanoform Finland Plc February 22, 2022 08:10 a.m.…
Invitation to Nanoform’s Q4 and full year 2021 report February 22, 2022
Press release Nanoform Finland Plc February 8, 20212 11:00 a.m.…
Nanoform signs GMP manufacturing program with TargTex following formulation success
Press release Nanoform Finland Plc February 4, 2022 08:10 a.m.…
Nanoform sets two new near-term business targets for 2022
Insider information Nanoform Finland Plc January 3, 2022 08:10 a.m.…
Nanoform financial calendar for 2022
Company Announcement Nanoform Finland Plc December 10, 2021 04.45 p.m.…
Nanoform Interim Report January – September 2021
The strong momentum continues: all near-term business targets for 2021…
Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting on November 17, 2021
Company release Nanoform Finland Plc November 17, 2021 03:00 p.m.…
Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021
Press release Nanoform Finland Plc November 17, 2021 10:15 a.m.…
Nanoform signs GMP agreement and achieves near-term business target
Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m.…
Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System
Press release Nanoform Finland Plc November 12, 2021 11:00 a.m.…
Invitation to presentation of Nanoform’s Q3/2021 report on November 25, 2021
Press release Nanoform Finland Plc November 11, 2021 11:00 a.m.…
Nanoform’s trailblazing progress earns recognition from prestigious industry awards
Our impressive achievements have been recognized across the board, with…
Nanoform convenes EGM to elect Jeanne Thoma as board member
Company Announcement Nanoform Finland Plc October 18, 2021 08:10 a.m.…
Notice to the Extraordinary General Meeting of NANOFORM FINLAND PLC
Company Announcement Nanoform Finland Plc October 18, 2021 08:10 a.m.…
Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen
Company Announcement Nanoform Finland Plc October 18, 2021 08:10 a.m.…
Nanoform receives funding to solve challenges for global health
Press release Nanoform Finland Plc September 29, 2021 03:45 p.m.…
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Company release Nanoform Finland Plc Sep 24th, 2021 05.30 p.m.…
Nanoform shortlisted for the European Small and Mid-Cap Awards 2021
Press release Nanoform Finland Plc September 23, 2021 14:30 a.m.…
Nanoform technology delivers successful results for Herantis CDNF drug candidate
Press release Nanoform Finland Plc September 9, 2021 08:00 a.m.…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company release Nanoform Finland Plc August 27, 2021 04:30 p.m.…
Nanoform Interim Report January – June 2021
The strong momentum continues: Additional line capacity, more projects, new…
Invitation to presentation of Nanoform’s Q2/2021 report on August 26, 2021
Press release Nanoform Finland Plc August 12, 2021 11:00 a.m.…
Nanoform and Boehringer Ingelheim execute master services agreement
Press release Nanoform Finland Plc August 3, 2021 08:10 a.m.…
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Company release Nanoform Finland Plc June 14, 2021 03:00 p.m.…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company release Nanoform Finland Plc June 11, 2021 06:15 p.m.…
Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs
Company release Nanoform Finland Plc June 11, 2021 06:15 p.m.…
Nanoform raises its mid-term business targets for 2025
Insider information Nanoform Finland Plc June 2, 2021 04:00 p.m.…
Nanoform Interim Report January – March (Q1) 2021
Strong momentum continues: three new non-GMP lines commissioned, four new…
Nanoform and Celanese Explore Ways to Enhance Drug Delivery
Press release Nanoform Finland Plc May 25, 2021 04:00 p.m.…
Cynthia Schwalm transitions to Senior Advisor Business Development US, from her role as member of the Board of Directors
Company Announcement Nanoform Finland Plc May 20, 2021 09:10 p.m.…
Nanoform’s final clinical results confirm value proposition to the pharma industry
Press release Nanoform Finland Plc May 18, 2021 08:10 a.m.…
Invitation to presentation of Nanoform’s Q1/2021 report on May 27, 2021
Press release Nanoform Finland Plc May 12, 2021 11:00 a.m.…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company release Nanoform Finland Plc May 11, 2021 08:00 p.m.…
Nanoform and Aprecia collaborate to advance 3D printed Nanomedicines
Press release Nanoform Finland Plc April 21st, 2021 08:10 a.m.…
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Company release Nanoform Finland Plc April 8, 2021 06.30 p.m.…
Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs
Company release Nanoform Finland Plc April 7, 2021 5:30 p.m.…
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Company release Nanoform Finland Plc April 6, 2021 06:30 p.m.…
Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 6, 2021
Company release Nanoform Finland Plc April 6, 2021 11:00 a.m.…
Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates
Press release Nanoform Finland Plc March 31, 2021 08:10 a.m.…
Nanoform launches next-generation STARMAP® v2.0, the AI-based drug candidate selection tool for CESS®
Press release Nanoform Finland Plc March 22, 2021 08:10 a.m.…
NOTICE TO THE ANNUAL GENERAL MEETING OF NANOFORM FINLAND PLC
Company Announcement Nanoform Finland Plc March 10, 2021 23:00 Finnish…
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen
Yhtiötiedote Nanoform Finland Oyj 10.3.2021 klo 23.00 Suomen aikaa Kutsu Nanoform…
Nanoform Finland Plc: 5 633 803 new shares registered with the trade register
NOT FOR RELEASE, PUBLICATIONOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INOR INTO…
Nanoform Finland Plc successfully completes new share issue raising EUR 40 million
Insider information Nanoform Finland Plc March 9, 2021 23:20 Finnish time…
Nanoform Finland Plc announces its intention to carry out a new share issue to raise approximately EUR 40 million
Insider information Nanoform Finland Plc March 9, 2021 18:30 Finnish…
Nanoform 1-12/2020 report and new company near-term target introduced
Company Announcement Nanoform Finland Plc February 26, 2021 08:10 a.m.…
Nanoform sets new near-term business target for 2021 and 2022
Insider information Nanoform Finland Plc February 26, 2021 08:05 a.m.…
Additional Positive Interim Results from Nanoform’s Clinical Study
Insider information Nanoform Finland Plc February 24, 2021 08:10 a.m.…
Invitation to presentation of Nanoform’s year-end report for 2020 on February 26, 2021
Press release Nanoform Finland Plc February 12, 2021 11:00 a.m.…
Nanoform and Herantis sign Biologics Proof of Concept Agreement
Press release Nanoform Finland Plc February 9th, 2021 08:10 a.m.…
Nanoform’s Clinical Study Indicates Positive Interim Results
Insider information Nanoform Finland Plc January 22nd, 2021 at 08.10…
Finnish Foundation for Share Promotion and Nasdaq Helsinki has chosen Nanoform as the company of the month (article in Finnish)
Helsinki, Finland – Finnish Foundation for Share Promotion (Pörssisäätiö/Börsstiftelsen) and…
Nanoform sets a new near-term business target for 2021
Insider information Nanoform Finland Plc January 4th, 2021 at 08.10…
Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021
Helsinki, Finland – Nasdaq announced today the results of the…
Nanoform welcomed as a new member of Pharma Industry Finland (PIF)
Nanoform has been accepted as a new member of Pharma…
First dosing of nanoformed drug successfully accomplished
Press Release Nanoform Finland Plc December 21st, 2020 at 09.00…
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Inside information Nanoform Finland Plc December 17, 2020 at 7:15 p.m.…
Notification of major shareholdings according to Nanoform’s Articles of Association
PRESS RELEASE Nanoform Finland Plc December 8th, 2020 06.05 p.m.…
Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)
PRESS RELEASE Nanoform Finland Plc December 2nd, 2020 4 p.m.…
Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time
COMPANY RELEASE Nanoform Finland Plc, Interim Report January – September…
Nanoform launches technology for biologics and sets new near-term business target for 2021
Inside information Nanoform Finland Plc November 27th, 2020 at 07:50…
Invitation to presentation of Nanoform’s Q3 Report on November 27
PRESS RELEASE Nanoform Finland Plc November 16, 2020 11:00 a.m.…
Nanoform to present at Avanza Börsdag on November 18
PRESS RELEASE Nanoform Finland Plc November 11th, 2020 11:00 a.m.…
Amplifying Scientific Innovation Podcast
In Episode 5, Season 2 of the Amplifying Scientific Innovation…
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company Announcement October 23rd, 2020 at 7:00 p.m. Finnish time…
Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule
Inside information Nanoform Finland Plc October 20th, 2020 at 5:15…
Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade
Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade Nanoform…
Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs
COMPANY RELEASE September 2, 2020 at 03:00 p.m. Finnish time …
Nanoform expands global commercial team with US appointments
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle…
Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020
COMPANY RELEASE September 1, 2020 at 1:00 p.m. Finnish time…
NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST
COMPANY RELEASE NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT,…
Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen
Nanoform Finland Oyj:n (y-tunnus: 2730572-8) osakkeenomistajat kutsutaan ylimääräiseen yhtiökokoukseen, joka…
Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC
The shareholders of Nanoform Finland Plc (business ID: 2730572-8) are…
Nanoform convenes EGM to elect Cynthia Schwalm as board member
COMPANY RELEASE August 6, 2020 9:10 am Helsinki time Helsinki,…
Nanoform’s positive commercial momentum continues
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Company Announcement
June 25, 2020 at 4:00 p.m. Finnish time
Nanoform Finland Plc appoints Peter Hänninen as General Counsel
Press Release June 15, 2020 at 8:00 a.m. Finnish time…
Nanoform Finland Plc – Manager’s transactions – Edward Hæggström
Nanoform Finland Plc – Manager’s transactions – June 10, 2020…
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Nanoform Finland Plc – Manager’s transactions – June 10, 2020…
Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoform Finland Oyj:n listautumisannin lisäosakeoption toteuttaminen ja vakauttamisajan päättäminen
EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA LEVITTÄMINEN TAI JULKISTAMINEN OLISI LAINVASTAISTA.
Utnyttjande av övertilldelningsoptionen i noteringen av Nanoform Finland Plc och avbrytande av stabiliseringsperioden
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, NYA ZEELAND, AUSTRALIEN, JAPAN, HONGKONG, SINGAPORE ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION I VILKEN SÅDAN DISTRIBUTION, OFFENTLIGGÖRANDE ELLER PUBLICERING SKULLE STRIDA MOT GÄLLANDE REGLER.
De tio största aktieägarna i Nanoform Finland Plc efter genomförandet av noteringen
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, NYA ZEELAND, AUSTRALIEN, JAPAN, HONGKONG, SINGAPORE ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION I VILKEN SÅDAN DISTRIBUTION, OFFENTLIGGÖRANDE ELLER PUBLICERING SKULLE STRIDA MOT GÄLLANDE REGLER.
Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoform Finland Oyj:n kymmenen suurinta osakkeenomistajaa listautumisannin päättymisen jälkeen
EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA LEVITTÄMINEN TAI JULKISTAMINEN OLISI LAINVASTAISTA.
Erbjudandet i samband med noteringen av Nanoform har kraftigt övertecknats och kommer att genomföras som planerat – handel i aktierna förväntas inledas imorgon
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, NYA ZEELAND, AUSTRALIEN, JAPAN, HONGKONG, SINGAPORE ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION I VILKEN SÅDAN DISTRIBUTION, OFFENTLIGGÖRANDE ELLER PUBLICERING SKULLE STRIDA MOT GÄLLANDE REGLER.
The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoformin listautumisanti on huomattavasti ylimerkitty ja listautuminen toteutetaan suunnitellusti – osakkeiden kaupankäynnin odotetaan alkavan huomenna
EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA LEVITTÄMINEN TAI JULKISTAMINEN OLISI LAINVASTAISTA.
The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoformin Instituutioanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty
EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA LEVITTÄMINEN TAI JULKISTAMINEN OLISI LAINVASTAISTA.
Det institutionella erbjudandet i Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, NYA ZEELAND, AUSTRALIEN, JAPAN, HONGKONG, SINGAPORE ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION I VILKEN SÅDAN DISTRIBUTION, OFFENTLIGGÖRANDE ELLER PUBLICERING SKULLE STRIDA MOT GÄLLANDE REGLER.
Nanoformin Yleisöanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty
EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA LEVITTÄMINEN TAI JULKISTAMINEN OLISI LAINVASTAISTA.
Erbjudandet i samband med noteringen av Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, NYA ZEELAND, AUSTRALIEN, JAPAN, HONGKONG, SINGAPORE ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION I VILKEN SÅDAN DISTRIBUTION, OFFENTLIGGÖRANDE ELLER PUBLICERING SKULLE STRIDA MOT GÄLLANDE REGLER.
Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Nanoform Finland Plc har ansökt om upptagande till handel av dess aktier på Nasdaq First North Premier Growth Market Finland och Nasdaq First North Premier Growth Market Sweden
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, NYA ZEELAND, AUSTRALIEN, JAPAN, HONGKONG, SINGAPORE ELLER SYDAFRIKA ELLER ANNAN JURISDIKTION I VILKEN SÅDAN DISTRIBUTION, OFFENTLIGGÖRANDE ELLER PUBLICERING SKULLE STRIDA MOT GÄLLANDE REGLER.
Nanoform Finland Oyj on hakenut osakkeidensa listausta Nasdaq First North Premier Growth Market Finlandissa ja Nasdaq First North Premier Growth Market Swedenissä
EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA LEVITTÄMINEN TAI JULKISTAMINEN OLISI LAINVASTAISTA.
Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN…
Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa
Nanoform Finland Oyj (“Nanoform” tai “Yhtiö”) julkisti tänään suunnitellun listautumisantinsa…
Nanoform offentliggör en fast teckningskurs och publicerar ett prospekt för den planerade parallellnoteringen av dess aktier på Nasdaq First North Premier Growth Market i Finland & Sverige
Nanoform Finland Plc (”Nanoform” eller ”Bolaget”) offentliggjorde i dag teckningskursen…
Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa
Nanoform Finland Oyj (“Nanoform” tai “Yhtiö”) julkisti tänään suunnitellun listautumisantinsa…
Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden
Nanoform announces a fixed subscription price and publishes a prospectus…
Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille
Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth…
Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden
Nanoform intends to launch an initial public offering and dual…
Nanoform avser att genomföra ett erbjudande och att parallellnoteras på Nasdaq First North Premier Growth Market i Finland & Sverige
Nanoform Finland Plc (”Nanoform” eller ”Bolaget”), ett bolag som erbjuder…
Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille
Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth…
Nanoform awarded GMP certification
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine…
Nanoform appoints Miguel Calado as Chairman of the Board
Nanoform has appointed Miguel Calado as Chairman of the Board.
A message from Nanoform regarding COVID-19
The COVID-19 pandemic is evolving rapidly, and we would like to assure our customers, partners, and suppliers that we are diligently monitoring the situation and follow the most up-to-date World Health Organization, EU, and local government guidelines.
Nanoform and Orion collaborate on next-generation drug development
Nanoform and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform’s award-winning CESS® technology to new chemical entities.
Nanoform establishes US subsidiary
Nanoform has established Nanoform USA Inc., a wholly owned subsidiary in the US.
Nanoform files for GMP certification
Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.
Nanoform wins the CPhI Excellence in Pharma Award for Formulation
Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.
Nanoform nominated for CPhI Award!
We are delighted to have been shortlisted as a finalist for the CPhI Award in the Excellence in Pharma: Formulation category.
Nanoform and AstraZeneca Initiate Technology Evaluation
Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
Nanoform strengthens board with appointment of Mads Laustsen
Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Nanoform appoints Mike Rea as Strategic Innovation Advisor
Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
Nanoform appoints Director of Investor Relations following international growth
Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
Nanoform continues strategic growth with €10 million private placement
Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.
Nanoform announces major rebrand
Nanoform has unveiled a new brand identity and website. The evolution of Nanoform’s brand reflects how the company is using innovation to transform the pharmaceutical industry and support its global partners as they develop life-changing medicines.
Our CCO, Christian Jones, interviewed at EBD Group’s BIO-Europe Spring 2019.
Our CCO, Christian Jones, recently discussed the advantages of our nanonization services with Mike Ward at EBD Group’s BIO-Europe Spring 2019. Watch the Scrip video to learn more:
Nanoform accelerates growth with Director of Project Management appointment
Nanoform accelerates growth with Director of Project Management appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, will appoint Miguel Cansado as its Director of Project Management.
Nanoform awarded with a Seal of Excellence from the European Commission
Nanoform awarded with a Seal of Excellence from the European Commission Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project.
Nanoform strengthens GMP capabilities with Head of Manufacturing appointment
Nanoform strengthens GMP capabilities with Head of Manufacturing appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr David Rowe as its Head of Manufacturing.
Nanoform strengthens board with appointment of Vice Chairman
Nanoform strengthens board with appointment of Vice Chairman Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Miguel Calado as Vice Chairman of the Board.
Construction of Nanoform’s GMP manufacturing plant rapidly progresses
Nanoform, an innovative drug enabling nanotechnology company, has announced significant progress in the construction of its new 600m2 GMP manufacturing plant, located at Cultivator II in Viikki Life Science Park, Finland.
Nanoform signs world-leading sparse data AI expert
Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Prof Jukka Corander as Head of AI.
Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer
Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Niklas Sandler as Chief Technology Officer.
Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment
Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Gonçalo Rebelo de Andrade as Chief of Business Operations.
Nanoform continues rapid expansion with construction of GMP manufacturing plant
Nanoform, an innovative drug enabling nanotechnology company, has announced the construction of a GMP manufacturing plant to provide API ‘solution to particle’ nanonization for clinical trials.
Nanoform set to globalize its technology with appointment of a Chief Commercial Officer
Nanoform, a Helsinki, Finland-based drug particle engineering and nanotechnology company, is set to globalize its novel nanonization technology with the appointment of Christian Jones as Chief Commercial Officer.
Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology
Nanoform, an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, is continuing its strategic growth through a significant €7 million investment, with Vator Securities acting as the sole bookrunner.